Rigontec GmbH raises €4.8m in a second closing of its Series A financing

26-Mar-2015 - Germany

Rigontec GmbH announced it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new investment brings the total Series A to €14.25 million and adds two further highly experienced investors to Rigontec’s investor base alongside Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK and High-Tech Gründerfonds (HTGF).
 
The proceeds of the Series A financing round will be used to progress Rigontec's lead drug candidate into clinical proof-of-concept studies, and to expand Rigontec’s pipeline based on its proprietary RNA-sensing technology. Holger Reithinger from Forbion Capital Partners and Sten Verland from Sunstone Capital have joined Rigontec's Board of Directors.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...